• 1
    Afdhal NH. Epidemiology, risk factors, and pathogenesis of gallstones. In: AfdhalNH, ed. Gallbladder and Biliary Tract Diseases. New York: Marcel Dekker, Inc., 2000: 127146.
  • 2
    Gilat T, Somjen GJ, Mazur Y, Leikin-Frenkel A, Rosenberg R, Halpern Z, Konikoff FM. Fatty acid bile acid conjugates (FABACs)—new molecules for the prevention of cholesterol crystallization in bile. Gut 2001; 48:7579. MEDLINE
  • 3
    Gilat T, Leikin-Frenkel A, Goldiner I, Laufer H, Halpern Z, Konikoff FM. Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice. Lipids 2002 (in press).
  • 4
    Khanuja B, Cheah YC, Hunt M, Nishima PM, Wang DQ, Chen HW, Billheimer JT, et al: Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc Natl Acad Sci U S A 1995; 92:77297733. MEDLINE
  • 5
    Turley SD, Dietschy JM. Re-evaluation of the 3alfa-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 1978; 19:924928. MEDLINE
  • 6
    Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29:10751080. MEDLINE
  • 7
    Bartlett GR. Phosphorous assay in column chromatography. J Biol Chem 1959; 234:466468.
  • 8
    Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 1972; 286:18. MEDLINE
  • 9
    Salen G, Tint GS, Shefer S. Oral dissolution treatment of gallstones with bile acids. Semin Liver Dis 1990; 10:181190. MEDLINE
  • 10
    Fromm H, Roat JW, Gonzales V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. Gastroenterology 1983; 85:12571264. MEDLINE
  • 11
    Beynen AC. Lack of regression of preestablished gallstones in mice. Lipids 1987; 22:542543. MEDLINE
  • 12
    Gilat T, Konikoff FM. Pregnancy and the biliary tract. Can J Gastroenterol 2000; 14(Suppl D):55D59D. MEDLINE
  • 13
    Everhart JE. Contributions of obesity and weight loss to gallstone disease. Ann Intern Med 1993; 119:10291035. MEDLINE
  • 14
    Gilat T, Konikoff FM. Current concepts of cholesterol gallstone formation and the prevention of biliary cholesterol crystallization, Book of abstracts, EASL 2001: 5961.
  • 15
    Konikoff FM, Leikin-Frenkel A, Goldiner I, Michowich M, Brezovsky E, Haratz D, Gilat T. Biliary and systemic effects of fatty acid bile acid conjugates (FABACs). Aliment Pharmacol Ther (submitted 2002).
  • 16
    Lee SP, Hayashi A, Kim YS. Biliary sludge: curiosity or culprit? Hepatology 1994; 20:523525. MEDLINE
  • 17
    Leikin-Frenkel A, Goldiner I, Gilat T, Halpern Z, Konikoff FM. Structure function relationships and lack of toxicity of fatty acid bile acid conjugates (FABACs). Gastroenterology 2001; 120(Suppl 1):A13.